主要文件

查看所有文档

Y0001062

氯沙坦钾

Name: 氯沙坦钾
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

2-丁基-4-氯-1-[[2′-(2H-四唑-5-基)[1,1′-联苯]-4-基]甲基]- 1H-咪唑-5-甲醇钾盐, 2-丁基-4-氯-1-{[2′-(1H-四唑-5-yl)(1,1′-联苯)-4-yl]甲基}-1H-咪唑-5-甲醇单钾盐, DuP 753, MK 954, 钾5-(4′-((2-丁基-4-氯-5-(羟甲基)-1H-咪唑-1-基)甲基)-[1,1′-联苯]-2-yl)四唑-1-ide

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₂₂ClKN₆O

化学文摘社编号:

124750-99-8

分子量:

461.00

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329831243

MDL number:

MFCD02092704

Beilstein/REAXYS Number:

5845770

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

losartan

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]

InChI

1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1

InChI key

OXCMYAYHXIHQOA-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Losartan potassium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

氯沙坦钾是一种口服、强效、选择性的竞争血管紧张素II受体1型 (AT1)拮抗剂。氯沙坦钾用于治疗高血压。

口服、强效、选择性的竞争血管紧张素II受体1型 (AT1)拮抗剂。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 氯沙坦钾

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome.

Christiane Pees et al.

The American journal of cardiology, 112(9), 1477-1483 (2013-07-23)

Since 2008, when angiotensin II type I receptor blockade with losartan was introduced in the prevention of cardiovascular manifestation of Marfan syndrome (MFS), a specific treatment to address the cardiovascular lesions became available. The present study aimed to compare the

A risk-benefit assessment of losartan potassium in the treatment of hypertension.

L M Burrell

Drug safety, 16(1), 56-65 (1997-01-01)

Losartan potassium is the first of a new class of orally active antihypertensive drugs which antagonise the action of angiotensin (AT) II at the AT1 receptor subtype. Losartan potassium is converted by the liver to the active metabolite E-3174, which

Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects.

M Burnier et al.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 13(1), S23-S28 (1995-07-01)

The evaluation of a new drug in normotensive volunteers provides important pharmacodynamic and pharmacokinetic information as long as the compound has a specific mechanism of action which can be evaluated in healthy subjects as well as in patients. The purpose

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0001062	04061837584022
Y0001062-50MG	04061832618555